• Xiaoxia Dai, Tao Feng, Xuejuan Zhang, and Kaishu Li.
• Xiaoxia Dai, Department of Respiratory Medicine, Binzhou People's Hospital, Shandong, 256600, China.
• Pak J Med Sci. 2020 Nov 1; 36 (7): 1688-1692.

ObjectiveTo analyze the clinical effect of budesonide/fomoterol combined with montelukast in the treatment of chronic persistent asthma.MethodsNinety-four patients with asthma who came to our hospital for treatment from April 2017 to April 2019 were randomly divided into control group and observation group, with 47 patients in each group. The control group was treated with budesonide/formoterol, and the observation group was treated with montelukast on the basis of the control group. The treatment effect of the two groups was observed and compared.ResultsThe total efficacy rate of the observation group was significantly higher than that of the control group (P<0.05); the daytime symptom score and nighttime symptom score of the observation group were significantly higher than those of the control group (P<0.05). The pulmonary function indexes of the two groups after treatment were significantly higher than that before treatment, and the improvement of the observation group was more significant (P<0.05); the FeNO and EO levels of the observation group after treatment were superior to those of the control group, and the difference was statistically significant (P<0.05).ConclusionBudesonide/formoterol powder inhalation combined with montelukast can effectively improve the lung function, reduce the level of inflammatory factors, and accelerate the regression of symptoms in the treatment of chronic persistent asthma. It is worth clinical application.Copyright: © Pakistan Journal of Medical Sciences.

4 keywords...

hide…